

FRAMEWORK FOR CLINICAL EVALUATION  
OF DEVICES FOR MALE CIRCUMCISION



WHO Library Cataloguing-in-Publication Data

Framework for clinical evaluation of devices for male circumcision.

1.Circumcision, Male – instrumentation. 2.Circumcision, Male – trends. 3.HIV infections – prevention and control.  
4.Device approval. I.World Health Organization.

ISBN 978 92 4 150435 5

(NLM classification: WC 503.6)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

**FRAMEWORK FOR CLINICAL EVALUATION  
OF DEVICES FOR MALE CIRCUMCISION**

**SEPTEMBER 2012**

---

## TABLE OF CONTENTS

<b>Abbreviations and acronyms</b>	<b>3</b>
<b>Acknowledgments</b>	<b>4</b>
<b>Executive summary</b>	<b>5</b>
<b>1. Purpose and background</b>	<b>6</b>
1.1 Purpose	6
1.1.1 Objective of this document	6
1.1.2 Target audiences	7
1.2 Background	7
1.2.1 Male circumcision and prevention of HIV and other sexually transmitted infections	7
1.2.2 Expansion of male circumcision programmes	8
1.2.3 Male circumcision procedures	9
1.2.4 Structure of document	10
<b>2. Evaluation of adult male circumcision devices</b>	<b>11</b>
<b>3. Regulatory issues in the development, testing and registration of devices</b>	<b>14</b>
<b>4. Clinical issues in development and evaluation of male circumcision devices</b>	<b>17</b>
4.1 Demonstrating safety and effectiveness	17
4.2 Clinical studies in the country of origin	18
4.3 Clinical studies in the setting of intended final use	20
4.3.1 Case series	22
4.3.2 Comparative studies	22
4.3.3 Acceptability studies	23
4.3.4 Field studies	24
4.4 Minimum clinical studies for review of safety and effectiveness	26
4.5 Studies to extend use to other populations or types of patients	27
4.5.1 Bridging studies to extend use to additional types of clients	27
4.5.2 Safety studies in special patient groups	27
4.6 Assessment of other innovations in male circumcision procedure	28
4.7 Paediatric devices	28
4.8 Informing programme implementation	28
4.8.1 Implementation process	28
4.8.2 Pilot implementation studies	30
4.8.3 Sequencing pilot implementation studies with evolving global recommendations	31
4.9 Surveillance and reporting of adverse events as programmes are scaled up	32

<b>5. Ensuring quality and safety of male circumcision devices: the WHO Prequalification Process</b>	<b>33</b>
<b>6. Marketing, pricing, supply and post market surveillance</b>	<b>35</b>
6.1 Direct marketing of devices	35
6.2 Public-sector pricing	35
6.3 Manufacturer's capability	35
6.4 Post-market surveillance	36
<b>References</b>	<b>37</b>

## **TABLES**

<b>Table 1.</b> Device characteristics and evaluation criteria for assessing male circumcision devices	12
<b>Table 2.</b> Types of studies and information on male circumcision device from country of origin	20
<b>Table 3.</b> Clinical trials in settings of intended final use	21
<b>Table 4.</b> Field studies: pilot and cohort studies in settings of intended final use	25
<b>Table 5.</b> Twelve recommendations on designing pilot projects with scaling up in mind	29
<b>Table 6.</b> Potential pilot implementation studies	31

---

## ABBREVIATIONS AND ACRONYMS

AE	adverse event
CFR	Code of Federal Regulations
EU	European Union
FDA	US Food and Drug Administration
GHTF	Global Harmonization Task Force
HIV	human immunodeficiency virus
HPV	human papillomavirus
HSV-2	herpes simplex virus-2
ISO	International Organization for Standardization
MDD	Medical Device Directive (European Union)
PMA	pre-market approval
SFDA	State Food and Drug Administration (People's Republic of China)
UNAIDS	Joint United Nations Programme on HIV/AIDS
VMMC	Voluntary medical male circumcision
WHO	World Health Organization

## ACKNOWLEDGMENTS

This framework benefits from advice and documentation provided by lead researchers in the field through their publications and publicly available documents as well as from discussions with Timothy Hargreave, John Krieger, Philip Li and other urologists on various issues relating to surgical techniques and research. Further, much of the information and impetus for this document was generated by the participants at a symposium, Meeting the Demand for Male Circumcision, convened in March 2008 by the Forum for Collaborative HIV Research in collaboration with The Bill and Melinda Gates Foundation, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) in Kampala, Uganda. The framework was revised following a consultation, held in March 2009 in Nairobi, Kenya, to review manufacturing, clinical and regulatory requirements for male circumcision devices to support programme expansion in high HIV incidence settings in Africa. We gratefully acknowledge the comments and insights of the participants at that consultation: Kawango Agot, Jackson Amone, Robert Bailey, Mark Barone, Kasonde Bowa, Peter Cherutitch, Emily Gumkowski, Timothy Hargreave, Mohammed Ibrahim, Fred Kambuni, Philip Li, Hilda Matumo, Walter Obiero, Christine Rousseau, Christopher Andrew Samkange, Kanwarjit KJ Singh, David Sokal, Christopher Charles Tapfumaneyi, Stephen Watya and J. Masasabi Wekesa. Thanks are due to Agnes Chidanyika and Ariane van der Straten for compiling and updating the framework following that meeting and to Jeanette Twell, WHO Health Systems and Services for contributions on the regulatory sections. The draft framework was critically reviewed by the WHO Technical Advisory Group on Innovations in Male Circumcision in July 2011 and adopted as the basis for formal assessment of circumcision devices and other innovations in male circumcision after revision and clarification of the minimum extent of clinical data required; thanks are due to Renee Ridzon and Tim Hargreave who contributed extensively to critical reviews. Tim Farley conceived and led the development of the document throughout the process; Julia Samuelson contributed to and coordinated publication of the 2012 version.

## EXECUTIVE SUMMARY

Male circumcision has been shown to reduce the risk of heterosexually acquired HIV infection in men. The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) recommend male circumcision as a priority intervention in countries and settings with a high incidence of HIV and a low prevalence of male circumcision.

Male circumcision devices have the potential to accelerate delivery of male circumcision programmes in resource-limited settings by reducing the time to perform the operation, by simplifying the procedure so that providers can perform it more easily and in some circumstances by making the procedure more acceptable to clients than a surgical approach. Devices are widely used for circumcision in infants and young boys, but experience in post-pubertal boys and adults is limited, particularly in the countries in the African region where rapid expansion of male circumcision programmes for HIV prevention is most urgent.

Regulations governing approval of medical devices require clinical evaluation but may only require limited clinical trials for devices that are used as aids to surgery or remain external to the body. This includes male circumcision devices. As male circumcision programmes for HIV prevention are a public health intervention and involve large numbers of healthy men, a more rigorous assessment of the clinical safety, efficacy, acceptability and cost-effectiveness of male circumcision devices is required. *The Framework for clinical evaluation of devices for male circumcision* is intended to be used by (a) product developers seeking to develop new male circumcision devices or to modify existing devices for use in adult male circumcision programmes in resource-limited settings; (b) clinicians involved in testing devices for acceptability and suitability for use in resource-limited settings, particularly by mid-level providers; (c) regulators responsible for overseeing the development, testing and evaluation of male circumcision devices; and (d) programme managers and sponsors supporting expansion of programmes for male circumcision to prevent HIV infection.

The framework focuses mainly on clinical requirements for assessing the suitability of a device for male circumcision within public health HIV prevention programmes in resource-limited settings and, secondarily, on regulatory and manufacturing considerations. A series of steps and clinical studies is described to evaluate the clinical performance, safety and acceptability of a new male circumcision device, as are the minimum sizes of these different studies. These studies include clinical studies in

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28360](https://www.yunbaogao.cn/report/index/report?reportId=5_28360)

